IceCure Medical (NASDAQ:ICCM) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of IceCure Medical (NASDAQ:ICCM) in a research report sent to investors on Tuesday, Benzinga reports. HC Wainwright currently has a $3.00 target price on the stock.

Separately, Alliance Global Partners increased their target price on shares of IceCure Medical from $1.90 to $2.90 and gave the stock a buy rating in a research report on Wednesday, March 20th.

IceCure Medical Stock Performance

Shares of NASDAQ:ICCM opened at $0.74 on Tuesday. The company has a 50 day moving average price of $0.96 and a 200 day moving average price of $1.15. IceCure Medical has a 1-year low of $0.52 and a 1-year high of $1.57. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.88 and a current ratio of 3.39. The stock has a market capitalization of $33.73 million, a price-to-earnings ratio of -2.24 and a beta of 0.57.

IceCure Medical (NASDAQ:ICCM) last posted its quarterly earnings data on Tuesday, May 28th. The company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08). IceCure Medical had a negative net margin of 444.30% and a negative return on equity of 101.66%. The firm had revenue of $0.74 million during the quarter, compared to analyst estimates of $0.80 million. During the same quarter last year, the business posted ($0.08) EPS. On average, research analysts anticipate that IceCure Medical will post -0.28 EPS for the current fiscal year.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.